December 2, 2022 7:53am

Indications:  2 Positive Indication and 2 Negative Indications

News: Beam Therapeutics (BEAM +$0.78 or +1.70% pre-open) the U.S. FDA has lifted the clinical hold and cleared the Investigational New Drug (IND) application for BEAM-201 for the treatment of relapsed/refractory T-cell acute lymphoblastic leukemia (T-ALL)/T-cell lymphoblastic lymphoma (T-LL). BEAM-201 is a potent and specific anti-CD7, multiplex-edited, allogeneic chimeric antigen receptor T-cell development candidate.

A daily report may say little or a lot and its final judgement may be inconclusive; yet it serves as insurance that all indications are being examined, evaluated and reported.

I don’t seek fame, do podcasts or give speeches; what I do is write this blog/newsletter to inform investors with facts and supporting numbers focused on what they need to hear that others won’t say or write about - truth!

8:00 a.m. edition


Remember that overnight and pre-open actions in futures don't necessarily translate into actual trading in the coming day’s session.

 

Dow futures are DOWN -0.10% or (-35 points), S&P futures are DOWN -0.04% or (-2 point) and NASDAQ futures are DOWN -0.10% or (-12 points) early in the pre-open – so far,

Stock futures fell slightly Friday,

European markets were lower,

Asia-Pacific markets fell.

 

Henry’omics:

We need to understand the macro to comprehend the micro re “our” universe of cell and gene therapy companies …

From last night, indexes closed mixed on Thursday after an inflation measure PCE (personal consumption index) watched by the Fed came in a little lighter than expected.

The Dow closed DOWN – 193.77 points (-0.56%), the S&P close DOWN -3.43 points (-0.08%) while the Nasdaq closed UP +14.45 points (+0.13%)

Economic Data Docket: initial jobless claims ahead of the November jobs report due out Friday.

 

Thursday’s (12/1) … RegMed Investors’ (RMi) closing bell: hitting the brakes as December begins.” … https://www.regmedinvestors.com/articles/12725

RegMed investors (RMi) Research Note: Intellia Therapeutics (NTLA) prices offering of 6.25 million shares priced at $45.80.” … https://www.regmedinvestors.com/articles/12723

 

Ebb and flow:

Q4 – December – 1 negative close

·         November -1 holiday, 14 negative and 8 positive closes

·         October -1 neutral, 11 positive and 9 negative closes

Q3/22 –

·         September – 1 holiday, 10 positive and 11 negative closes

·         August – 1 neutral, 11 positive and 11 negative closes

·         July - 1 holiday, 10 negative and 10 positive closes

 

Companies in my headlights – It’s your decision; I provide ideas and context: INDICATIONS

Positive Indications:

Beam Therapeutics (BEAM) closed down -$0.36 to $45.83 after Wednesday’s +$2.58, Tuesday’s +$0.43 and Monday’s -$1.10 with a positive +$0.78 or +1.70% pre-open indication on news <in title>.

Intellia Therapeutics (NTLA) closed down -5.66 to $45.80 after Wednesday’s +$3.46, Tuesday’s -$0.26 and Monday’s -$1.42 Friday’s -$0.21 with a positive +$0.99 or +2.16% pre-open indication.

 

Negative Indications:

Verve Therapeutics (VERV) closed down -0.66 to $22.57 after Wednesday’s +$1.49 with a negative -$1.07 or -4.74% pre-open indication.

CRISPR Therapeutics (CRS)closed down -$0.45 to $54.34 with a negative -$0.79 or -1.455 pre-open indication.

 

The BOTTOM LINE: I try to keep it simple and short!

Indecision of any moves in this sector is wrapped cynicism.

In the very short term, investors may want to be cautious about making new buys. The market and sector face a big technical test with inflation and jobs reports likely to play a key role in how that plays out.

“While it's fine putting money to work in the current stock market, keep your exposure on the conservative side with small positions to start. Just because the stock market is in a confirmed uptrend doesn't mean you have to be 100% invested. And don't be afraid to take a 10% gain if you have it, given the choppy nature of the market.” <IBD>

Amid the ongoing cell and gene therapy sector volatility, “our” universe’s trend remains " in a constant correction." That means that … lately we are investors are safer on the sidelines.

Reiterating, “The real question that should be asked is how many companies are at the end of sentiments …  leash? I stick to my view of anticipating the risks – as my careers focus has been “warning analysis”.

Insight is about understanding perception and also about putting into context what is relevant to expectation fulfillment

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

All investments are subject to risks. Investors should consider investment objectives.

Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions securities referred to in this publication.